Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study

Objectives To assess whether prednisone use and/or disease activity score (DAS) are associated with the development of hyperglycaemia and diabetes in rheumatoid arthritis (RA).Methods We included 504 non-diabetic early RA patients from the BeSt study (Dutch acronym for treatment strategies). Patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Cornelia F Allaart, Tom W J Huizinga, Sytske Anne Bergstra, Willem Lems, Sjoerd M van der Kooij, Joy Ardjuna van der Pol
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/10/2/e004246.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849315349712863232
author Cornelia F Allaart
Tom W J Huizinga
Sytske Anne Bergstra
Willem Lems
Sjoerd M van der Kooij
Joy Ardjuna van der Pol
author_facet Cornelia F Allaart
Tom W J Huizinga
Sytske Anne Bergstra
Willem Lems
Sjoerd M van der Kooij
Joy Ardjuna van der Pol
author_sort Cornelia F Allaart
collection DOAJ
description Objectives To assess whether prednisone use and/or disease activity score (DAS) are associated with the development of hyperglycaemia and diabetes in rheumatoid arthritis (RA).Methods We included 504 non-diabetic early RA patients from the BeSt study (Dutch acronym for treatment strategies). Patients were randomised to four DAS-steered treatment arms and followed for 10 years. The associations between DAS and prednisone use with glucose levels and the occurrence of hyperglycaemia over time were assessed with linear and logistic mixed effects regression models. Development of diabetes was analysed with Cox regression. Sensitivity analyses were performed in patients who had a first episode of hyperglycaemia.Results 31 of 504 patients (6.2%) with a mean age of 54 years developed diabetes during follow-up; 11 of these (35%) had received prior treatment with prednisone. Prednisone use was not associated with development of hyperglycaemia or diabetes after correction for multiple testing in main or sensitivity analyses. In the main analyses, DAS was significantly associated with development of diabetes (HR 1.802 per 1 point DAS increase, 95% CI 1.284 to 2.529) but not with glucose levels nor hyperglycaemia. In patients with previous hyperglycaemia, DAS was associated with glucose levels, recurrence of hyperglycaemia and diabetes.Conclusions In non-diabetic early RA patients, the use of prednisone was not associated with developing hyperglycaemia or diabetes. However, high DAS increased the risk of diabetes. Potential risks associated with prednisone use may have been mitigated by its effect on DAS.
format Article
id doaj-art-4b0cfea9794a4909b48cbbbb8d244991
institution Kabale University
issn 2056-5933
language English
publishDate 2024-04-01
publisher BMJ Publishing Group
record_format Article
series RMD Open
spelling doaj-art-4b0cfea9794a4909b48cbbbb8d2449912025-08-20T03:52:10ZengBMJ Publishing GroupRMD Open2056-59332024-04-0110210.1136/rmdopen-2024-004246Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt studyCornelia F Allaart0Tom W J Huizinga1Sytske Anne Bergstra2Willem Lems3Sjoerd M van der Kooij4Joy Ardjuna van der Pol51 Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The NetherlandsDepartment of Rheumatology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands5 Rheumatology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The NetherlandsRheumatology, Haga Hospital, Den Haag, The NetherlandsDepartment of Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The NetherlandsObjectives To assess whether prednisone use and/or disease activity score (DAS) are associated with the development of hyperglycaemia and diabetes in rheumatoid arthritis (RA).Methods We included 504 non-diabetic early RA patients from the BeSt study (Dutch acronym for treatment strategies). Patients were randomised to four DAS-steered treatment arms and followed for 10 years. The associations between DAS and prednisone use with glucose levels and the occurrence of hyperglycaemia over time were assessed with linear and logistic mixed effects regression models. Development of diabetes was analysed with Cox regression. Sensitivity analyses were performed in patients who had a first episode of hyperglycaemia.Results 31 of 504 patients (6.2%) with a mean age of 54 years developed diabetes during follow-up; 11 of these (35%) had received prior treatment with prednisone. Prednisone use was not associated with development of hyperglycaemia or diabetes after correction for multiple testing in main or sensitivity analyses. In the main analyses, DAS was significantly associated with development of diabetes (HR 1.802 per 1 point DAS increase, 95% CI 1.284 to 2.529) but not with glucose levels nor hyperglycaemia. In patients with previous hyperglycaemia, DAS was associated with glucose levels, recurrence of hyperglycaemia and diabetes.Conclusions In non-diabetic early RA patients, the use of prednisone was not associated with developing hyperglycaemia or diabetes. However, high DAS increased the risk of diabetes. Potential risks associated with prednisone use may have been mitigated by its effect on DAS.https://rmdopen.bmj.com/content/10/2/e004246.full
spellingShingle Cornelia F Allaart
Tom W J Huizinga
Sytske Anne Bergstra
Willem Lems
Sjoerd M van der Kooij
Joy Ardjuna van der Pol
Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study
RMD Open
title Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study
title_full Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study
title_fullStr Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study
title_full_unstemmed Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study
title_short Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study
title_sort prednisone use disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis a 10 year subanalysis of the best study
url https://rmdopen.bmj.com/content/10/2/e004246.full
work_keys_str_mv AT corneliafallaart prednisoneusediseaseactivityandtheoccurrenceofhyperglycaemiaanddiabetesinpatientswithearlyrheumatoidarthritisa10yearsubanalysisofthebeststudy
AT tomwjhuizinga prednisoneusediseaseactivityandtheoccurrenceofhyperglycaemiaanddiabetesinpatientswithearlyrheumatoidarthritisa10yearsubanalysisofthebeststudy
AT sytskeannebergstra prednisoneusediseaseactivityandtheoccurrenceofhyperglycaemiaanddiabetesinpatientswithearlyrheumatoidarthritisa10yearsubanalysisofthebeststudy
AT willemlems prednisoneusediseaseactivityandtheoccurrenceofhyperglycaemiaanddiabetesinpatientswithearlyrheumatoidarthritisa10yearsubanalysisofthebeststudy
AT sjoerdmvanderkooij prednisoneusediseaseactivityandtheoccurrenceofhyperglycaemiaanddiabetesinpatientswithearlyrheumatoidarthritisa10yearsubanalysisofthebeststudy
AT joyardjunavanderpol prednisoneusediseaseactivityandtheoccurrenceofhyperglycaemiaanddiabetesinpatientswithearlyrheumatoidarthritisa10yearsubanalysisofthebeststudy